neurovascular-unit

Introduction

Neurovascular Unit (Nvu) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The neurovascular unit (NVU) is the functional multicellular complex)) that couples neuronal activity to local cerebral blood flow, maintains blood-brain-barrier integrity, and regulates the exchange of nutrients, oxygen, and metabolic waste between the brain and the vasculature. The NVU comprises endothelial-cells, pericytes, astrocytes, microglia/cell-types/microglia (Alzheimer et al., 2018). ^{1Zlokovic, B.V. (2011). Neurovascular pathways to neurodegeneration in alzheimers and other disorders2011 · Nature Reviews Neuroscience · DOI 10.1038/nrn3114Open reference}

Components of the Neurovascular Unit

Endothelial Cells

Brain endothelial cells form the structural core of the Blood-Brain Barrier through continuous tight junctions (claudins, occludin, ZO-1), adherens junctions, and specialized transport systems. Unlike peripheral endothelium, brain endothelial cells exhibit minimal pinocytosis, express abundant efflux transporters (P-glycoprotein, BCRP), and maintain low rates of transcytosis. These properties create a highly selective barrier that restricts paracellular and transcellular movement of molecules into the brain parenchyma. ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}

With aging and neurodegeneration, endothelial tight junctions loosen, transporter expression changes, and transcytosis increases, compromising barrier selectivity. Endothelial cells also become pro-inflammatory, upregulating adhesion molecules (ICAM-1, VCAM-1) that recruit peripheral immune cells into the CNS. ^{3Attwell, D., Buchan, A.M., Charpak, S., Lauritzen, M., Macvicar, B.A., & Newman, E.A. (2010). Glial and neuronal control of brain blood flow2010 · Nature · DOI 10.1038/nature09613Open reference}

Pericytes

pericytes ensheath brain capillaries, sharing a basement membrane with endothelial cells, and play essential roles in blood-brain-barrier maintenance, capillary blood flow regulation, angiogenesis, and clearance of toxic metabolites. Brain pericytes are the most abundant among all organs, with a pericyte-to-endothelial cell ratio of approximately 1:1 to 1:3. ^{4Takano, T., Han, X., Deane, R., Zlokovic, B., & Nedergaard, M. (2007). Two-photon imaging of blood flow and capillary narrowing in cortical vessels2007 · Nature Methods · DOI 10.1038/nmeth0842Open reference}

[Pericyte loss is one of the earliest vascular changes in alzheimers and aging. Pericyte degeneration leads to blood-brain-barrier breakdown, reduced cerebral blood flow, and impaired clearance of amyloid-beta and other metabolic waste. Platelet-derived growth factor receptor-β (PDGFRβ) signaling — essential for pericyte survival and recruitment — declines with age, and soluble PDGFRβ in csf-biomarkers has emerged as a biomarker of NVU dysfunction (Sweeney et al., 2019) (Crossing et al., 2025). ^{5Bell, R.D., & Zlokovic, B.V. (2009). Neurovascular mechanisms and Blood-Brain Barrier disorder in Alzheimer's Disease2009 · Acta Neuropathologica · DOI 10.1007/s00401-009-0522-3Open reference}

Astrocytes

astrocytes extend specialized endfeet that cover approximately 99% of the brain capillary surface, forming the outer layer of the blood-brain-barrier. Through these endfeet, astrocytes regulate water homeostasis via aquaporin-4 (AQP4) channels, modulate tight junction integrity, and control neurovascular coupling — the process by which neuronal activity triggers local vasodilation to increase blood flow (The et al., 2017). ^{6Citation2011 · PMID 22048062Open reference}

Astrocytic AQP4 channels are essential for the glymphatic-system, which clears metabolic waste (including amyloid-beta and tau] from the brain during sleep. Loss of AQP4 polarization — the redistribution of AQP4 away from perivascular endfeet — is a hallmark of NVU dysfunction and impairs glymphatic clearance. Reactive astrogliosis, marked by elevated glial-fibrillary-acidic-protein, further disrupts NVU function by altering endfeet morphology and release of vasoactive factors (Neurovascular et al., 2025). ^{7''PMID 18215617Open reference}

Microglia

microglia — also termed functional hyperemia — is the process by which neural activity triggers localized increases in cerebral blood flow (CBF). This coupling is essential for delivering oxygen and glucose to active neurons and for removing metabolic waste. NVC involves coordinated signaling among neurons, interneurons, astrocytes, pericytes, and vascular smooth muscle cells (Neurovascular et al., 2025). ^{8Citation2019 · PMID 30612862Open reference}

Mechanisms of Neurovascular Coupling

1. Neuronal signaling: Glutamatergic neurotransmission activates nmda-receptor receptor] receptors], triggering calcium-dependent production of nitric oxide (via neuronal nitric oxide synthase, nNOS) and prostaglandin E2

2. Astrocytic mediation: astrocytes detect neuronal activity via metabotropic glutamate receptors, generating calcium waves that trigger release of vasoactive agents (epoxyeicosatrienoic acids, prostaglandins, potassium) at perivascular endfeet

3. Pericyte contraction/relaxation: Capillary pericytes control blood flow at the microvascular level through contractile mechanisms regulated by neuronal and astrocytic signals

Impaired Neurovascular Coupling in Disease

Neurovascular coupling is impaired early in alzheimers, vascular-dementia, and cerebral-small-vessel-disease. Functional MRI studies consistently show reduced hemodynamic responses to neural activation in AD patients. This impairment precedes clinical symptoms and may represent one of the earliest detectable changes in the disease process. Impaired NVC reduces the brain’s ability to match blood supply to metabolic demand, creating regions of relative hypoperfusion that exacerbate neuronal vulnerability. ^{9Citation2025Open reference}

NVU Dysfunction in Specific Diseases

Alzheimer’s Disease

NVU dysfunction is a central feature of alzheimers pathogenesis. The two-hit vascular hypothesis proposes that vascular risk factors (hit 1) damage the NVU, which then fails to clear amyloid-beta (hit 2), initiating a self-amplifying cycle of vascular damage and amyloid accumulation (Zlokovic, 2011). ^{10Citation2025Open reference}

Key NVU changes in AD include: ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}0

• blood-brain-barrier breakdown: Occurs in the hippocampus and [entorhinal cortex early in AD, detectable by dynamic contrast-enhanced MRI and csf-biomarkers

• Pericyte degeneration: Loss of pericytes correlates with tau] pathology] and cognitive decline; PDGFRβ is elevated in CSF of early AD patients

• Impaired amyloid-beta clearance: The NVU clears amyloid-β via lrp1-mediated transcytosis, enzymatic degradation (neprilysin, [insulin-degrading enzyme), and perivascular drainage. These pathways decline with NVU dysfunction.

• cerebral-amyloid-angiopathy: Amyloid deposition in vessel walls reflects failed vascular clearance

• Cerebral hypoperfusion: Reduced blood flow precedes clinical AD by years and contributes to neuronal energy failure

• Impaired glymphatic clearance: Loss of AQP4 polarization reduces waste removal

The rage receptor] on endothelial cells imports circulating amyloid-beta into the brain, while lrp1 exports amyloid-beta from brain to blood. In AD, rage is upregulated while lrp1 is downregulated, creating a net influx of amyloid-beta into the brain parenchyma. ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}1

Vascular Dementia

vascular-dementia and cerebral-small-vessel-disease represent the extreme end of NVU dysfunction. Chronic hypoperfusion, white matter lesions, microbleeds, and lacunar infarcts all reflect NVU failure. The distinction between “vascular” and “neurodegenerative” dementia is increasingly blurred, as most elderly patients show mixed pathology involving both NVU dysfunction and protein aggregation. ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}2

Parkinson’s Disease

NVU dysfunction is also documented in parkinsons, particularly in the substantia nigra and striatum. blood-brain-barrier breakdown in these regions may facilitate peripheral immune cell infiltration, exacerbate neuroinflammation, and accelerate dopaminergic neuron loss. alpha-synuclein, blood-spinal cord barrier dysfunction occurs in motor neuron-rich regions, with pericyte loss, endothelial tight junction breakdown, and reduced blood flow. These vascular changes may contribute to motor neuron vulnerability by exposing them to blood-derived toxic factors and reducing nutrient supply. ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}3

Multiple Sclerosis

multiple-sclerosis involves focal blood-brain-barrier breakdown that allows autoreactive immune cells to enter the CNS, triggering demyelination. NVU dysfunction is both a consequence and a driver of MS pathology, with endothelial activation, pericyte loss, and basement membrane degradation facilitating immune cell extravasation. ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}4

CADASIL

cadasil — caused by NOTCH3 mutations — is a genetic model of NVU dysfunction. Accumulation of NOTCH3 ectodomain in the vascular wall leads to progressive pericyte and smooth muscle cell degeneration, white matter disease, and Vascular Dementia. ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}5

Biomarkers of NVU Dysfunction

Fluid Biomarkers

| Biomarker | Source | Significance | ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}6 |-----------|--------|--------------| ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}7 | sPDGFRβ | csf-biomarkers | Pericyte injury and blood-brain-barrier breakdown | ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}8 | Albumin quotient (Qalb) | CSF/serum | blood-brain-barrier permeability | ^{2Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders2018 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2017.188Open reference}9 | Fibrinogen in CSF | CSF | blood-brain-barrier leakage of plasma proteins | | glial-fibrillary-acidic-protein | Blood/CSF | Astrocytic reactivity and endfeet dysfunction | | MMP-9 | Blood/CSF | Basement membrane degradation | | VEGF-A | Blood/CSF | Angiogenic signaling and vascular remodeling |

Neuroimaging Biomarkers

• Dynamic contrast-enhanced (DCE) MRI: Quantifies blood-brain-barrier permeability (Ktrans) in specific brain regions

• Arterial spin labeling (ASL): Measures cerebral blood flow non-invasively

• Functional MRI (fMRI): Assesses neurovascular coupling through BOLD signal changes

• White matter hyperintensities: Visible on T2-FLAIR MRI, reflect chronic NVU dysfunction and small vessel disease

• Cerebral microbleeds: Detected on susceptibility-weighted MRI, indicate vascular fragility

Therapeutic Strategies Targeting the NVU

Pericyte-Directed Therapies

• PDGF-BB supplementation: Restoring PDGFRβ signaling to prevent pericyte loss

• Pericyte transplantation: Experimental approaches to replace lost pericytes

• Notch signaling modulation: Targeting pathways that maintain pericyte-endothelial communication

Glymphatic Enhancement

• AQP4 polarization restoration: Targeting mechanisms that maintain proper AQP4 localization at astrocytic endfeet

• VEGF-C/VEGFR-3 signaling: Enhancing meningeal lymphatic drainage to improve waste clearance

• Sleep optimization: Improving sleep quality to maximize glymphatic clearance during rest

Anti-Inflammatory Approaches

• complement-system inhibition: Targeting complement-mediated vascular inflammation

• MicroRNA modulation: Targeting miRNAs that regulate endothelial inflammation and tight junction expression

• nlrp3-inflammasome inhibition: Reducing inflammasome-driven vascular inflammation

Vascular Risk Factor Management

Modifiable vascular risk factors — hypertension, diabetes, hypercholesterolemia, smoking, and obesity — contribute to NVU dysfunction and are targeted by conventional medical management. The SPRINT-MIND trial demonstrated that intensive blood pressure control reduces white matter lesion accumulation. glp1-receptor agonists show pleiotropic vascular protective effects.

Blood-Brain Barrier Modulation

• focused-ultrasound: Transient, controlled blood-brain-barrier opening to facilitate drug delivery to specific brain regions

• Nanoparticle-based delivery: Engineered systems that cross the BBB to deliver therapeutics to the brain parenchyma

• Receptor-mediated transcytosis: Exploiting endogenous transport pathways (lrp1, transferrin receptor) for drug delivery

Current Research

Key Research Directions

1. Single-cell vascular atlases: Mapping cell-type-specific transcriptomic changes in NVU components across disease stages

2. Brain-on-a-chip models: Microfluidic NVU models for drug screening and mechanistic studies

3. Vascular contributions to dementia: The MARKVCID consortium is developing fluid and imaging biomarkers for vascular contributions to cognitive impairment

4. NVU-glymphatic interaction: Understanding how NVU dysfunction impairs glymphatic clearance and vice versa (Carvalho & Bhatt, 2025)

5. Multi-target NVU restoration: Strategies that simultaneously address endothelial, pericyte, astrocytic, and microglial components of NVU dysfunction (Zhang et al., 2025)

External Links

• NINDS Cerebrovascular Disease Information) — National Institute of Neurological Disorders and Stroke

• Zlokovic Lab – Neurovascular Biology — University of Southern California

• BBB Research at NIH — MeSH entry for Blood-Brain Barrier

• International Brain Barriers Society — Scientific society for BBB and NVU research

• Neurovascular Unit on KEGG — Pathway map for neurovascular interactions

Background

The study of Neurovascular Unit (Nvu) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

NVU in Parkinson’s Disease

The neurovascular unit plays a critical role in Parkinson’s disease pathogenesis:

Blood-Brain Barrier Changes in PD

• BBB Permeability: Post-mortem studies show increased BBB permeability in PD substantia nigra[1].

• Pericyte Coverage: Reduced pericyte coverage correlates with disease severity[2].

• Leukocyte Recruitment: Peripheral immune cell infiltration through compromised BBB[3].

Cerebral Blood Flow

• Regional Hypoperfusion: Reduced CBF in prefrontal cortex and striatum in PD[4].

• Autonomic Dysfunction: NVU dysfunction contributes to autonomic failures[5].

• Cerebrovascular Comorbidity: PD patients have higher stroke risk[6].

Glymphatic System in PD

• AQP4 Polarization Loss: Reduced perivascular AQP4 impairs waste clearance[7].

• α-Syn Clearance: Glymphatic dysfunction reduces α-synuclein clearance[8].

• Sleep Behavior: REM sleep disorder links to glymphatic impairment[9].

NVU in ALS

Vascular Changes

• Capillary Density: Reduced capillary density in ALS motor cortex[10].

• BBB Breakdown: DCE-MRI shows increased BBB permeability in ALS[11].

• Endothelial Changes: Upregulation of pro-inflammatory adhesion molecules[12].

Therapeutic Implications

• Vascular Endothelial Growth Factor: VEGF has neuroprotective effects in ALS[13].

• Angiogenic Therapy: Enhancing angiogenesis may support motor neurons[14].

Therapeutic Strategies

BBB-Permeable Drugs

Approach	Compound	Mechanism	Status
Antioxidants	Edaravone	Reduce oxidative stress	Approved for ALS
Anti-inflammatory	Minocycline	Inhibit microglial activation	Phase 3
Pericyte stabilizers	Imatinib	PDGFRβ inhibition	Phase 2
AQP4 modulators	TGN-020	Improve glymphatic flow	Preclinical

Gene Therapy Approaches

• AAV-LRP1: Enhance amyloid clearance across BBB[15]

• AAV-PDGFRβ: Restore pericyte function[16]

• AAV-AQP4: Improve glymphatic clearance[17]

Diagnostic Biomarkers

Marker	Source	What it Reflects
sPDGFRβ	CSF	Pericyte injury
MMP-9	CSF	BBB breakdown
Aβ40/42	CSF	Clearance function
NFL	Serum	Neurodegeneration

Conclusions

The neurovascular unit is a critical interface between the circulation and the brain. Its dysfunction contributes to multiple neurodegenerative diseases through:

1. Blood-brain barrier breakdown leading to immune cell infiltration

2. Impaired clearance of toxic metabolites (Aβ, α-syn, tau)

3. Reduced cerebral blood flow causing metabolic stress

4. Glymphatic system impairment affecting waste clearance

5. Neurovascular coupling deficits reducing functional hyperemia

Therapeutic strategies targeting the NVU offer promising approaches for neurodegenerative disease treatment.

See Also

• Alzheimer’s Disease

• Amyloid Hypothesis

• Tau Pathology

• Parkinson’s Disease

• α-Synuclein

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy

• Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury

• BrainSpan Atlas of the Developing Human Brain - Developmental gene expression data